Drug Shortage Report for TRIESENCE

Last updated on 2022-01-04 History
Report ID 140457
Drug Identification Number 02368676
Brand name TRIESENCE
Common or Proper name Triesence 1mL Susp
Company Name NOVARTIS PHARMACEUTICALS CANADA INC
Market Status MARKETED
Active Ingredient(s) TRIAMCINOLONE ACETONIDE
Strength(s) 40MG
Dosage form(s) SUSPENSION
Route of administration INTRAVITREAL INTRAVITREAL
Packaging size 1mL
ATC code S01BA
ATC description ANTIINFLAMMATORY AGENTS
Reason for shortage Delay in shipping of the drug.
Anticipated start date 2021-10-11
Actual start date 2021-10-14
Estimated end date 2022-01-14
Actual end date 2021-12-22
Shortage status Resolved
Updated date 2022-01-04
Company comments Production constraints limit product availability.
Health Canada comments
Tier 3 Status No
Contact Address 700 RUE SAINT-HUBERT
MONTREAL, QUEBEC
CANADA H2Y 0C1
Company contact information customer.relations@novartis.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v23 2022-01-04 French Compare
v22 2022-01-04 English Compare
v21 2021-12-16 French Compare
v20 2021-12-16 English Compare
v19 2021-10-29 French Compare
v18 2021-10-29 English Compare
v17 2021-10-19 French Compare
v16 2021-10-19 English Compare
v15 2021-10-12 French Compare
v14 2021-10-07 French Compare
v13 2021-10-07 English Compare
v12 2021-10-05 English Compare
v11 2021-09-27 French Compare
v10 2021-09-27 English Compare
v9 2021-09-27 English Compare
v8 2021-07-29 French Compare
v7 2021-07-29 English Compare
v6 2021-07-27 English Compare
v5 2021-07-13 French Compare
v4 2021-07-13 English Compare

Showing 1 to 20 of 23